+ data and comment +, page-2

Study: Post 2

6. Developments and Announcements:

The formation of "BETA"-Date 9/6/2000:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=163078

Date: 6/8/2001: Phytotherapy Technology Pty Ltd is a 25% shareholder in the company's subsidiary company Eiffel Research & Development Pty Ltd (formerly Bioactive Enhancement Technologies Pty Ltd)

Phase II clinical trials of its patented ZINC MONOGLYCEROLATE (ZMG) by Central Clinical Ltd of London had shown positive results against existing hydrocortisone treatment of Eczema.-Date 9/6/2000:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=163073

The name "Pharmaction Holdings Limited" was changed "Eiffel Technologies Limited" - Date 20/12/2000.

(a) Sheffield Pharmaceuticals Inc to apply Eiffel's patent pending technology- Date 21/11/2001:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=184044

(b) Amarin Corporation contract-Date 17/5/202:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=190416

Amarin's positive statement-Date 20/5/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=190480

Eiffel to acquire 100% of Eiffel Research and Development Pty Ltd (ERD)-Date 29/7/2002.
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=192759

(c) Profile Therapeutics plc (LSE: PTP), and Eiffel Technologies agreement- Date 1/7/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=191861

Investors Update-Date 29/7/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=192753

Breakthrough insulin study -Date15/8/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=193502

Announces the formation of its world-class Scientific Advisory Board-Date 8/10/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=195945

BattellePharma advised Eiffel that as the result of a refocus of its research and development investments, it will not continue the combined research activities with Eiffel-Date 12/11/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=197670

(d) Aradigm Corporation agreement-Date: 31/3/03:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=202713

(e) Agreement for its core technology with an unnamed major pharmaceutical company. Looking into NASDAQ listing- Date: 17/4/03:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=203383

(f) Oriel Therapeutics Inc. Agreement. Date: 18/7/2003:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=206411

(g) Meridica (UK) Agreement-Date 8/8/2003:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=207130

(h) Agreement with a large US-based drug delivery company to develop an inhalable form of insulin and to undertake pre-clinical research and development using product modified through Eiffel’s proprietary supercritical fluid (SCF) technology. Date 4/9/2003:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=208279

Recent articles about Eiffel:
http://www.eiffeltechnologies.com.au/html/news_articles.asp#bbyl

NB: (a) to (h), a total of 8 agreements in existence.

Gerry
End of study